Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study was to explore the effects of uric acid control on stone recurrence and renal function in patients with calculi of hyperuricemia through a prospective controlled study.
2020.1 -2020.12 patients with urolithiasis and hyperuricemia were enrolled in the urology department of our hospital (100 cases). The patients were informed of this study before operation and randomly divided into uric acid drug control group (n = 50) and non-drug control group (n = 50). The patients were followed up for 3 months, 6 months, 12 months and 18 months after operation.
Informations as age, sex, height, weight, calculation BMI, past medical history, history of gout, diabetes, hyperthyroidism, calcium supplements will be recorded.
Rapid blood glucose, serum total cholesterol, high density cholesterol, thyroid hormone detection, androgen, estrogen detection, serum sodium, potassium, chlorine, calcium, magnesium, phosphorus, serum uric acid will be tested.
Renogram test to evaluate the change of single renal function. The stones burden will be followed-up with ultrasound or kub or CT plain scan.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Uric acid drug control group | Experimental | For the uric acid control group, except that lifestyle changes were the same as those in the uric acid non-drug control group, non-drug uric acid control group was given febuxostat to reduce uric acid synthesis. Febuxostat is taken at a dose of 40 mg three times a week |
|
| Non-drug control group | Active Comparator | They are advised to live regularly after operation, drink plenty of water, drink more than 2000ml every day, reduce the intake of high purine food and fructose-rich beverages, increase the intake of fresh vegetables, control weight and exercise regularly. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Febuxostat 40mg Tab | Drug | For the uric acid control group, except that lifestyle changes were the same as those in the uric acid non-drug control group, non-drug uric acid control group was given febuxostat to reduce uric acid synthesis. Febuxostat is taken at a dose of 40 mg three times a week. |
| Measure | Description | Time Frame |
|---|---|---|
| Stone burdern stone burdern | Use ultrasound or kub or CT plain scan to follow up the patients. | Change from the base line of the stone's volume and quantity at 3 months. |
| Stone burdern stone burdern | Use ultrasound or kub or CT plain scan to follow up the patients. | Change from the base line of the stone's volume and quantity at 6 months. |
| Stone burdern stone burdern | Use ultrasound or kub or CT plain scan to follow up the patients. | Change from the base line of the stone's volume and quantity at 12 months. |
| Stone burdern stone burdern | Use ultrasound or kub or CT plain scan to follow up the patients. | Change from the base line of the stone's volume and quantity at 18 months. |
| Measure | Description | Time Frame |
|---|---|---|
| Renal function | Total and partial renal function | Change from the base line of GFR at 6 months after the operation. |
| Renal function | Total and partial renal function |
| Measure | Description | Time Frame |
|---|---|---|
| Serum uric acid level | Serum uric acid level | Chage from the base line at 3 months after the operation |
| Serum uric acid level | Serum uric acid level |
Inclusion Criteria:
.No clinical manifestations of urinary tract infection, urinary routine examination showed urinary tract infection, but urinary etiology test was negative (urinary routine leukocytosis), treated with broad-spectrum antibiotics for more than 3 days.
.Clinical manifestations of urinary tract infection, urine routine examination showed urinary tract infection, and patients with positive urinary etiology were treated with sensitive antibiotics for more than 7 days.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| JianMing Guo, PHD,M.D | Department of Urology, Zhongshan Hospital, Shanghai | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Shanghai Xuhui Central Hospital | Shanghai | Shanghai Municipality | 200031 | China |
Subject information, test results
Not provided
Not provided
Not provided
Not provided
Not provided
2020.1 -2020.12 patients with urolithiasis and hyperuricemia were enrolled in the urology department of our hospital (100 cases). The patients were informed of this study before operation and randomly divided into uric acid drug control group (n = 50) and non-drug control group (n = 50).
For non-drug control group: Patients are advised to live regularly after operation, drink plenty of water, drink more than 2000ml every day, reduce the intake of high purine food and fructose-rich beverages, increase the intake of fresh vegetables, control weight and exercise regularly.
Uric acid drug control group:or the uric acid control group, except that lifestyle changes were the same as those in the uric acid non-drug control group, non-drug uric acid control group was given febuxostat to reduce uric acid synthesis. Febuxostat is taken at a dose of 20 mg three times a week
Not provided
Not provided
Make a random table, and the patients are divided into the group according to the random table according to the order of enrollment.
Not provided
|
| Non-drug control group | Behavioral | All patients in the group are advised to live regularly after operation, drink plenty of water, drink more than 2000ml every day, reduce the intake of high purine food and fructose-rich beverages, increase the intake of fresh vegetables, control weight and exercise regularly |
|
| Change from the base line of GFR at 12 months after the operation. |
| Renal function | Total and partial renal function | Change from the base line of GFR at 18 months after the operation. |
| Chage from the base line at 6 months after the operation |
| Serum uric acid level | Serum uric acid level | Chage from the base line at 12 months after the operation |
| Serum uric acid level | Serum uric acid level | Chage from the base line at 18 months after the operation |
| ID | Term |
|---|---|
| C537757 | Renal hypouricemia |
| D052878 | Urolithiasis |
| ID | Term |
|---|---|
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069465 | Febuxostat |
| ID | Term |
|---|---|
| D013844 | Thiazoles |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided